Daniele Bertoglio1, Nicolas Halloin2, Stef De Lombaerde1,3, Aleksandar Jankovski4,5, Jeroen Verhaeghe1, Charles Nicaise2, Steven Staelens6. 1. Molecular Imaging Center Antwerp, University of Antwerp, Antwerp, Belgium. 2. URPhyM-NARILIS, University of Namur, Namur, Belgium. 3. Department of Nuclear Medicine, Antwerp University Hospital, Antwerp, Belgium. 4. Institute of NeuroScience, NEUR Division, Université Catholique de Louvain, Louvain, Belgium; and. 5. Department of Neurosurgery, CHU UCL Namur, Yvoir, Belgium. 6. Molecular Imaging Center Antwerp, University of Antwerp, Antwerp, Belgium; steven.staelens@uantwerpen.be.
Abstract
Traumatic spinal cord injury (SCI) is a neurologic condition characterized by long-term motor and sensory neurologic deficits as a consequence of an external physical impact damaging the spinal cord. Anatomic MRI is considered the gold-standard diagnostic tool to obtain structural information for the prognosis of acute SCI; however, it lacks functional objective information to assess SCI progression and recovery. In this study, we explored the use of synaptic vesicle glycoprotein 2A (SV2A) PET imaging to detect spinal cord lesions noninvasively after SCI. Methods: Mice (n = 7) and rats (n = 8) subjected to unilateral moderate cervical (C5) contusion were euthanized 1 wk after SCI for histologic and autoradiographic (3H-labeled (4R)-1-[(3-methylpyridin-4-yl)methyl]-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one [UCB-J]) investigation of SV2A levels. Longitudinal 11C-UCB-J PET/CT imaging was performed in sham (n = 7) and SCI rats (n = 8) 1 wk and 6 wk after SCI. Animals also underwent an 18F-FDG PET scan during the latter time point. Postmortem tissue SV2A analysis to corroborate in vivo PET findings was performed 6 wk after SCI. Results: A significant SV2A loss (ranging from -70.3% to -87.3%; P < 0.0001) was measured at the epicenter of the impact in vitro in both mouse and rat contusion SCI models. Longitudinal 11C-UCB-J PET imaging detected SV2A loss in SCI rats (-49.0% ± 8.1% at 1 wk and -52.0% ± 12.9% at 6 wk after SCI), with no change observed in sham rats. In contrast, 18F-FDG PET imaging measured only subtle hypometabolism (-17.6% ± 14.7%). Finally, postmortem 3H-UCB-J autoradiography correlated with the in vivo SV2A PET findings (r = 0.92, P < 0.0001). Conclusion: 11C-UCB-J PET/CT imaging is a noninvasive marker for SV2A loss after SCI. Collectively, these findings indicate that SV2A PET may provide an objective measure of SCI and thus represent a valuable tool to evaluate novel therapeutics. Clinical assessment of SCI with SV2A PET imaging is highly recommended.
Traumatic spinal cord injury (SCI) is a neurologic condition characterized by long-term motor and sensory neurologic deficits as a consequence of an external physical impact damaging the spinal cord. Anatomic MRI is considered the gold-standard diagnostic tool to obtain structural information for the prognosis of acute SCI; however, it lacks functional objective information to assess SCI progression and recovery. In this study, we explored the use of synaptic vesicle glycoprotein 2A (SV2A) PET imaging to detect spinal cord lesions noninvasively after SCI. Methods: Mice (n = 7) and rats (n = 8) subjected to unilateral moderate cervical (C5) contusion were euthanized 1 wk after SCI for histologic and autoradiographic (3H-labeled (4R)-1-[(3-methylpyridin-4-yl)methyl]-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one [UCB-J]) investigation of SV2A levels. Longitudinal 11C-UCB-J PET/CT imaging was performed in sham (n = 7) and SCI rats (n = 8) 1 wk and 6 wk after SCI. Animals also underwent an 18F-FDG PET scan during the latter time point. Postmortem tissue SV2A analysis to corroborate in vivo PET findings was performed 6 wk after SCI. Results: A significant SV2A loss (ranging from -70.3% to -87.3%; P < 0.0001) was measured at the epicenter of the impact in vitro in both mouse and rat contusion SCI models. Longitudinal 11C-UCB-J PET imaging detected SV2A loss in SCI rats (-49.0% ± 8.1% at 1 wk and -52.0% ± 12.9% at 6 wk after SCI), with no change observed in sham rats. In contrast, 18F-FDG PET imaging measured only subtle hypometabolism (-17.6% ± 14.7%). Finally, postmortem 3H-UCB-J autoradiography correlated with the in vivo SV2A PET findings (r = 0.92, P < 0.0001). Conclusion: 11C-UCB-J PET/CT imaging is a noninvasive marker for SV2A loss after SCI. Collectively, these findings indicate that SV2A PET may provide an objective measure of SCI and thus represent a valuable tool to evaluate novel therapeutics. Clinical assessment of SCI with SV2A PET imaging is highly recommended.
Authors: Christopher S Ahuja; Jefferson R Wilson; Satoshi Nori; Mark R N Kotter; Claudia Druschel; Armin Curt; Michael G Fehlings Journal: Nat Rev Dis Primers Date: 2017-04-27 Impact factor: 52.329
Authors: Ramona E von Leden; Reed G Selwyn; Shalini Jaiswal; Colin M Wilson; Guzal Khayrullina; Kimberly R Byrnes Journal: Neurosci Lett Date: 2016-04-12 Impact factor: 3.046
Authors: Jason F Talbott; John Russell Huie; Adam R Ferguson; Jacqueline C Bresnahan; Michael S Beattie; Sanjay S Dhall Journal: Radiol Clin North Am Date: 2018-11-17 Impact factor: 2.303
Authors: Charles Nicaise; Rajarshi Putatunda; Tamara J Hala; Kathleen A Regan; David M Frank; Jean-Pierre Brion; Karelle Leroy; Roland Pochet; Megan C Wright; Angelo C Lepore Journal: J Neurotrauma Date: 2012-11-23 Impact factor: 5.269
Authors: Eoin P Flanagan; Christopher H Hunt; Val Lowe; Jay Mandrekar; Sean J Pittock; Brian Patrick O'Neill; B Mark Keegan Journal: Mayo Clin Proc Date: 2013-11 Impact factor: 7.616